The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1043-1050 , November 2007

Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma

  • Stanley J. Szefler, MD

      Affiliations

    • Division of Pediatric Clinical Pharmacology and Allergy/Immunology, National Jewish Medical and Research Center, and the Departments of Pediatrics and Pharmacology, University of Colorado Health Sciences Center, Denver, Colo
    • Corresponding Author InformationReprint requests: Stanley J. Szefler, MD, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206.
    • ,
  • James W. Baker, MD

      Affiliations

    • Allergy Associates PC, Portland, Ore
    • ,
  • Tom Uryniak, MS

      Affiliations

    • AstraZeneca LP, Wilmington, Del
    • ,
  • Mitchell Goldman, MD, PhD

      Affiliations

    • AstraZeneca LP, Wilmington, Del
    • ,
  • Philip E. Silkoff, MD

      Affiliations

    • AstraZeneca LP, Wilmington, Del

Received 3 May 2007 ,Revised 8 August 2007 ,Accepted 29 August 2007.

References 

  1. National Asthma Education and Prevention Program . Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics—2002. J Allergy Clin Immunol. 2002;110:S141–S219
  2. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. American College of Chest Physicians/American College of Asthma, Allergy, and Immunology Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127:335–371
  3. Pulmicort Respules (budesonide inhalation suspension) package insert. Wilmington (DE): AstraZeneca LP; 2005;
  4. Kemp JP, Skoner DP, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol. 1999;83:231–239
  5. Baker JW, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics. 1999;103:414–421
  6. Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol. 1998;102:789–796
  7. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48
  8. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Pediatric Montelukast Study Group Montelukast for chronic asthma in 6- to 14-year-old children. JAMA. 1998;279:1181–1186
  9. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115:233–242
  10. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics. 2005;116:360–369
  11. Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr. 2005;147:213–220
  12. Sorkness CA, Lemanske RF, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al. Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007;119:64–72
  13. Vidal C, Fernández-Ovide E, Piñeiro J, Nuñez R, González-Quintela A. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol. 2001;86:655–658
  14. Peroni D, Bodini A, Miraglia Del Giudice M, Loiacono A, Baraldi E, Boner AL, et al. Effect of budesonide and montelukast in asthmatic children exposed to relevant allergens. Allergy. 2005;60:206–210
  15. Landgraff JM, Abetz L, Ware JE. Child Health Questionnaire (CHQ): a user's manual. Boston (MA): Health Act; 1996;
  16. Asmussen L, Olson LM, Grant EN, Fagan J, Weiss KB. Reliability and validity of the Children's Health Survey for Asthma. Pediatrics. 1999;104:e71
  17. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5:35–46
  18. Food and Drug Administration, Center for Drug Evaluation and Research. United States Department of Health and Human Services. Guidance for industry: orally inhaled and intranasal corticosteroids: evaluation of the effects on growth in children. March 2007. Available at: http://www.fda.gov/cder/guidance/5514fnl.pdf. Accessed October 3, 2007.
  19. Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117:45–52
  20. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354:1985–1997
  21. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A IFWIN Study Team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet. 2006;368:754–762

 Supported by AstraZeneca LP.

 Disclosure of potential conflict of interest: S. J. Szefler has consulting arrangements with AstraZeneca, GlaxoSmithKline, Aventis, Genentech, and Merck and has received grant support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, and Ross Pharmaceuticals. J. W. Baker has received grant support from GlaxoSmithKline, AstraZeneca, Apieron, NIOXX, Sanofi-Aventis, Amgen, ALK, Altana, MedPointe, Centocor, IVAX, JNJ, and Wyeth and is on the speakers' bureau for AstraZeneca, Novartis, and Merck. T. Uryniak, M. Goldman, and P. E. Silkoff own stock in and are employed by AstraZeneca.

PII: S0091-6749(07)01726-5

doi: 10.1016/j.jaci.2007.08.063

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1043-1050 , November 2007

Article Tools

* Image Usage & Resolution